Telum Therapeutics is focused on developing innovative antimicrobial products through the use of Engineered Phage Lytic Proteins (EPLs), which are derived from bacteriophages. These phage-encoded lytic proteins, also referred to as enzybiotics, are being explored as promising alternatives to traditional antibiotics, particularly in response to the growing issue of bacterial resistance. The company is actively engaged in creating a diverse collection of bacteria and phages sourced from various environments, including anthropogenic and cave explorations, to identify new bacteriophages and lytic enzymes that can serve therapeutic purposes against drug-resistant infections.

The development pipeline at Telum Therapeutics includes specific programs targeting serious multidrug-resistant infections caused by pathogens such as Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Their approach involves enhancing the antimicrobial activities of engineered phage lytic enzymes to combat these priority pathogens identified by the World Health Organization. By focusing on preclinical phases of development, Telum aims to provide effective treatments for life-threatening infections, including those caused by carbapenem-resistant strains and vancomycin-resistant Enterococcus, thereby addressing critical healthcare challenges posed by antibiotic resistance.

Spain

Telum Therapeutics SL is a global drug discovery biotechnology company specializing in the use of Innovative Phage Lytic Proteins as antibiotics.

Telum Therapeutics

Company Details